Physician
Paintsville Hospital Company, LLC
Paintsville Hospital Company, LLC was paid $15.46M by Medicaid between Jan 2018 and Jan 2022, across 232 billing codes. Its largest line is 99283, emergency room visit (moderate) — 17% of everything it billed.
33Billing provider infoPAINTSVILLE HOSPITAL COMPANY, LLC
PAINTSVILLE, KY 41240
PAINTSVILLE, KY 41240
33aNPI1538101688assigned 06/12/2006
33bProvider typeAnesthesiology Physician
28Total paid$15.46M
24GClaims443,997
24DCodes billed232
24AFirst – last monthJan 2018 – Jan 2022
Compared with peers
Next to other Anesthesiology Physician providers in Kentucky
Rank by total paid#2 of 46
Median peer was paid$68K
This provider vs. median228×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official COOPER, RANDY controls 18+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 123,199 | $4.45M | |
| 2019 | 119,938 | $4.12M | |
| 2020 | 110,025 | $3.50M | |
| 2021 | 87,800 | $3.27M | |
| 2022 | 3,035 | $117K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 17% | 20,919 | 16,153 | $2.61M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 14% | 10,764 | 8,295 | $2.19M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 14% | 7,497 | 3,903 | $2.17M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 8.8% | 6,607 | 4,377 | $1.37M |
| 70450 | Computed tomography, head or brain; without contrast material | 3.3% | 5,266 | 3,260 | $509K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.0% | 1,668 | 1,016 | $317K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.8% | 4,487 | 3,480 | $275K |
| G0378 | Hospital observation service, per hour | 1.6% | 2,960 | 1,442 | $240K |
| 71046 | Radiologic examination, chest; 2 views | 1.5% | 5,666 | 3,909 | $236K |
| 71250 | 1.4% | 2,662 | 1,623 | $221K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.2% | 4,802 | 2,088 | $192K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.2% | 2,660 | 1,595 | $182K |
220 more codes
| 72125 | Computed tomography, cervical spine; without contrast material | 1.1% | 1,558 | $177K |
| 71045 | Radiologic examination, chest; single view | 1.1% | 7,935 | $164K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.0% | 1,714 | $159K |
| 80053 | Comprehensive metabolic panel | 1.0% | 29,626 | $155K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 4,103 | $148K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 8,080 | $148K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,823 | $142K |
| 72131 | <1% | 1,526 | $142K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 3,381 | $140K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,059 | $139K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 4,013 | $138K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 13,358 | $133K |
| 36415 | Collection of venous blood by venipuncture | <1% | 48,888 | $132K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,637 | $131K |
| 80061 | Lipid panel | <1% | 7,061 | $107K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 818 | $104K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 4,369 | $98K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 7,250 | $97K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 23,944 | $96K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,251 | $94K |
| 72110 | <1% | 1,176 | $87K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 3,202 | $83K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,355 | $73K |
| 70486 | <1% | 326 | $70K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,782 | $68K |
| 73630 | <1% | 1,409 | $63K | |
| 72128 | <1% | 424 | $63K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 286 | $61K |
| 73564 | <1% | 1,222 | $60K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,801 | $57K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 210 | $56K |
| 82607 | <1% | 3,991 | $49K | |
| 73130 | <1% | 1,113 | $48K | |
| 73030 | <1% | 1,196 | $47K | |
| 97161 | <1% | 750 | $45K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 166 | $44K |
| 93975 | <1% | 406 | $43K | |
| 73610 | <1% | 1,175 | $40K | |
| 80074 | <1% | 1,034 | $39K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 133 | $37K |
| 82746 | <1% | 2,968 | $37K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,680 | $36K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,715 | $35K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 173 | $33K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,610 | $32K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,526 | $32K |
| 43202 | <1% | 87 | $29K | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,935 | $28K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,078 | $27K |
| 77080 | <1% | 406 | $26K | |
| 72072 | <1% | 273 | $26K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,038 | $25K |
| 87070 | <1% | 4,985 | $25K | |
| 84484 | <1% | 5,880 | $24K | |
| 87040 | <1% | 3,323 | $24K | |
| 84681 | <1% | 1,239 | $20K | |
| 86738 | <1% | 2,692 | $19K | |
| 73110 | <1% | 586 | $19K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 640 | $19K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,572 | $19K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 274 | $18K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,699 | $16K |
| 83735 | <1% | 5,421 | $16K | |
| 96376 | <1% | 1,003 | $16K | |
| 83880 | <1% | 1,251 | $15K | |
| 84439 | <1% | 2,079 | $15K | |
| 81001 | <1% | 5,915 | $15K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 657 | $14K |
| 72100 | <1% | 217 | $14K | |
| 87430 | <1% | 2,292 | $14K | |
| 72050 | <1% | 309 | $13K | |
| 85027 | <1% | 4,500 | $13K | |
| 86140 | <1% | 3,092 | $13K | |
| 83525 | <1% | 1,408 | $13K | |
| 84550 | <1% | 3,394 | $12K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,022 | $12K |
| 85651 | <1% | 3,837 | $12K | |
| 84703 | <1% | 3,855 | $12K | |
| 84403 | <1% | 598 | $12K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 17 | $12K |
| 87081 | <1% | 2,700 | $12K | |
| 83690 | <1% | 4,088 | $11K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 2,488 | $10K |
| 76536 | <1% | 103 | $10K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 696 | $10K |
| 74018 | <1% | 235 | $10K | |
| 85730 | <1% | 4,066 | $10K | |
| 86038 | <1% | 818 | $9K | |
| 82150 | <1% | 3,444 | $9K | |
| 83550 | <1% | 1,194 | $9K | |
| 85610 | <1% | 4,773 | $9K | |
| 95913 | <1% | 32 | $9K | |
| J3490 | Unclassified drugs | <1% | 1,388 | $8K |
| 93225 | <1% | 105 | $8K | |
| 83540 | <1% | 1,350 | $7K | |
| 73080 | <1% | 161 | $7K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,314 | $7K |
| 87186 | <1% | 1,389 | $7K | |
| 87075 | <1% | 1,051 | $7K | |
| 82803 | <1% | 869 | $7K | |
| 94760 | <1% | 889 | $7K | |
| 36600 | <1% | 1,242 | $6K | |
| 97010 | <1% | 611 | $6K | |
| 81003 | <1% | 5,879 | $6K | |
| 87077 | <1% | 1,546 | $5K | |
| 84402 | <1% | 241 | $5K | |
| 82962 | <1% | 2,359 | $5K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,894 | $5K |
| 93017 | <1% | 106 | $5K | |
| 90714 | <1% | 615 | $5K | |
| J0595 | Injection, butorphanol tartrate, 1 mg | <1% | 988 | $5K |
| 73090 | <1% | 103 | $5K | |
| 82043 | <1% | 932 | $5K | |
| 86431 | <1% | 843 | $4K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 261 | $4K |
| 84702 | <1% | 536 | $4K | |
| 94664 | <1% | 523 | $4K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 575 | $4K |
| 83605 | <1% | 903 | $4K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 14 | $3K |
| 82728 | <1% | 359 | $3K | |
| 93971 | <1% | 43 | $3K | |
| 73562 | <1% | 62 | $3K | |
| 84480 | <1% | 221 | $3K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,126 | $3K |
| 82553 | <1% | 842 | $3K | |
| 82550 | <1% | 1,238 | $3K | |
| 84481 | <1% | 186 | $3K | |
| 73560 | <1% | 81 | $3K | |
| 85378 | <1% | 883 | $3K | |
| 73590 | <1% | 96 | $3K | |
| 72040 | <1% | 31 | $3K | |
| J1020 | Injection, methylprednisolone acetate, 20 mg | <1% | 557 | $2K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 267 | $2K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 220 | $2K |
| 87205 | <1% | 936 | $2K | |
| 86677 | <1% | 112 | $2K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 70 | $2K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 138 | $2K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 88 | $2K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 338 | $2K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,847 | $1K |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 400 | $1K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,501 | $1K |
| 87420 | <1% | 142 | $1K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 181 | $1K |
| 93226 | <1% | 63 | $1K | |
| 72192 | <1% | 12 | $1K | |
| 84436 | <1% | 181 | $1K | |
| 87076 | <1% | 266 | $1K | |
| 0012A | <1% | 74 | $1K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 209 | $903.42 |
| 84154 | <1% | 80 | $900.74 | |
| 80320 | <1% | 80 | $826.13 | |
| 76642 | <1% | 17 | $823.41 | |
| 82140 | <1% | 86 | $816.04 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 95 | $815.12 |
| 0011A | <1% | 60 | $781.87 | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 132 | $768.23 |
| 86318 | <1% | 65 | $707.63 | |
| 86701 | <1% | 58 | $701.86 | |
| 72220 | <1% | 15 | $693.02 | |
| 12001 | <1% | 83 | $682.60 | |
| 77065 | Tomosynthesis, mammo | <1% | 17 | $594.67 |
| 80299 | <1% | 130 | $589.20 | |
| C1780 | Lens, intraocular (new technology) | <1% | 17 | $568.41 |
| 76775 | <1% | 15 | $543.77 | |
| 96367 | <1% | 61 | $520.53 | |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 34 | $486.59 |
| J2300 | Injection, nalbuphine hydrochloride, per 10 mg | <1% | 82 | $440.99 |
| 73502 | <1% | 12 | $420.66 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 274 | $397.70 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 84 | $387.79 |
| 80076 | <1% | 65 | $363.79 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 173 | $348.38 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 38 | $327.87 |
| 84100 | <1% | 159 | $291.87 | |
| 84153 | <1% | 23 | $198.62 | |
| 86592 | <1% | 58 | $178.66 | |
| 73565 | <1% | 32 | $161.30 | |
| 95885 | <1% | 34 | $160.00 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 57 | $156.52 |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 12 | $132.28 |
| G0008 | Administration of influenza virus vaccine | <1% | 20 | $115.81 |
| 80346 | <1% | 16 | $107.82 | |
| 90686 | <1% | 34 | $96.28 | |
| 80335 | <1% | 15 | $89.55 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 281 | $83.97 |
| 80329 | <1% | 13 | $82.30 | |
| 80348 | <1% | 13 | $79.66 | |
| 80372 | <1% | 13 | $79.30 | |
| 80367 | <1% | 13 | $76.66 | |
| 80361 | <1% | 13 | $76.66 | |
| 80354 | <1% | 13 | $76.66 | |
| 80365 | <1% | 13 | $76.66 | |
| 80362 | <1% | 13 | $76.66 | |
| 80373 | <1% | 13 | $76.66 | |
| 80338 | <1% | 13 | $74.34 | |
| 80332 | <1% | 13 | $74.34 | |
| 80369 | <1% | 13 | $73.42 | |
| 80368 | <1% | 13 | $73.38 | |
| 80366 | <1% | 13 | $71.34 | |
| 83992 | <1% | 41 | $66.56 | |
| 80342 | <1% | 13 | $66.46 | |
| 80358 | <1% | 13 | $66.02 | |
| 80324 | <1% | 16 | $62.90 | |
| 80353 | <1% | 13 | $62.02 | |
| 80339 | <1% | 13 | $60.58 | |
| 80357 | <1% | 13 | $60.46 | |
| 80359 | <1% | 13 | $53.02 | |
| 80371 | <1% | 13 | $50.02 | |
| 80360 | <1% | 13 | $50.02 | |
| 80375 | <1% | 13 | $47.50 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 17 | $42.73 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 55 | $35.34 |
| J2780 | Injection, ranitidine hydrochloride, 25 mg | <1% | 19 | $32.85 |
| 86308 | <1% | 13 | $25.22 | |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | <1% | 17 | $11.65 |
| C9399 | Unclassified drugs or biologicals | 0% | 80 | $0.00 |
| A9270 | Non-covered item or service | 0% | 77 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCOOPER, RANDY (SVP FINANCE OP/AUTHORIZED OFFICIAL)
| Provider | Location | Paid |
|---|---|---|
| Jackson Hospital Corporation | Jackson, KY | $34.90M |
| Deming Hospital Corporation | Deming, NM | $34.61M |
| Hospital of Louisa, INC. | Louisa, KY | $27.77M |
| Hospital of Barstow INC | Barstow, CA | $16.88M |
| San Miguel Hospital Corporation | Las Vegas, NM | $13.21M |
| Tooele Hospital Corporation | Tooele, UT | $11.66M |
| Forrest City Arkansas Hospital Company LLC | Forrest City, AR | $7.42M |
| MMC of Nevada LLC | Mesquite, NV | $2.60M |
| Fort Payne Hospital Corporation | Fort Payne, AL | $2.60M |
| Williamston Hospital Corporation | Williamston, NC | $2.31M |
| Waukegan Illinois Hospital Company LLC | Waukegan, IL | $2.30M |
| Southwest Kidney Institute Vascular Center LLC | Tempe, AZ | $850K |
| Evanston Hospital Corporation | Evanston, WY | $378K |
| Marion Hospital Corporation | Marion, IL | $220K |
| Anna Hospital Corporation | Anna, IL | $217K |
| National Healthcare of MT Vernon INC | Mount Vernon, IL | $158K |
| Red Bud Illinois Hospital Company LLC | Red Bud, IL | $36K |
| Tooele Hospital Corporation | Tooele, UT | $5K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.